Myostatin regulates skeletal muscle size via the activin receptor IIB (ActRIIB). However, its effect on muscle energy metabolism and energy dependent muscle function remains largely unexplored. This question needs to be solved urgently since various therapies for neuromuscular diseases based on blockade of ActRIIB signaling are being developed. Here we show in mice that four months of pharmacological abrogation of ActRIIB signaling by treatment with soluble ActRIIB-Fc triggers extreme muscle fatigability. This is associated with elevated serum lactate levels and a severe metabolic myopathy in the mdx mouse, an animal model of Duchenne muscular dystrophy. Blockade of ActRIIB signaling down-regulates Porin, a crucial ADP/ATP shuttle between cytosol and mitochondrial matrix leading to a consecutive deficiency of oxidative phosphorylation as measured by in vivo Phophorus Magnetic Resonance Spectroscopy ( 31 P-MRS). Further, ActRIIB blockade reduces muscle capillarization, which further compounds the metabolic stress. We show that ActRIIB regulates key determinants of muscle metabolism, such as Pparβ, Pgc1α, and Pdk4 thereby optimizing different components of muscle energy metabolism. In conclusion, ActRIIB signaling endows skeletal muscle with high oxidative capacity and low fatigability. The severe metabolic side effects following ActRIIB blockade caution against deploying this strategy, at least in isolation, for treatment of neuromuscular disorders.
INTRODUCTION
Skeletal muscle has inbuilt control mechanisms to prevent overgrowth. This function is executed, at least in part, by secreted molecules including members of the transforming growth factor-β (TGF-β) family, especially myostatin 1 . Myostatin signals via its transmembrane activin receptor IIB (ActRIIB) and suppression of this pathway stimulates muscle growth 2, 3 . In the past few years, strategies have been developed to treat muscular dystrophies, muscle wasting and cachexia by blocking the myostatin/ActRIIB pathway with first of many clinical trials already being concluded (ClinicalTrials.gov NCT01099761, NCT01519349, NCT01423110, NCT01669174, NCT01601600, NCT01433263). However, it remains a matter of controversy whether the hypertrophic muscles that form as a result of blocking myostatin/ActRIIB signaling confer any functional benefit, because a number of groups have reported loss of specific force of larger muscles in myostatin knockout mice and a faster fatigability (Mstn -/-) 4-6 . In addition, myostatin knockout leads to a change of muscle contractile and metabolic characteristics towards a "glycolytic" phenotype 5, 7, 8 , commonly attributed to a change in muscle specification during development. In contrast to the constitutive myostatin deficiency of Mstn -/mice, postnatal treatment with soluble activin IIB receptor (sActRIIB-Fc) in adult mice blocks myostatin/ActRIIB signaling and increases muscle force without altering the fiber type composition 9, 10 . Similar results have been obtained in the mdx mouse model of Duchenne muscular dystrophy 11, 12 . However, a recent transcriptome profiling demonstrated a down-regulation of genes involved in oxidative phosphorylation and mitochondrial function following treatment with sActRIIB-Fc. 13 Another study revealed a faster decline of muscle force following repetitive stimulation 14 . Whether those changes reflect solely a change towards a faster muscle phenotype or a relevant mitochondrial dysfunction is presently unknown. In the view of ongoing clinical trials we need to address the question of how myostatin blockade affects the metabolism of dystrophic muscle in mdx mice, which already has a preexisting deficit of mitochondrial function [15] [16] [17] . Here we explored the hypothesis that ActRIIB signaling is a key regulator of oxidative metabolism in the adult muscle. We thus set out to systematically investigate in adult wild-type and mdx mice, how postnatal blockade of ActRIIB signaling using sActRIIB-Fc might affect muscle energy metabolism and energy dependent muscle function.
Our data conclusively show the importance of ActRIIB signaling as a pivotal link that acts to balance muscle size and strength against endurance capacity via optimization of energy metabolism.
RESULTS

ActRIIB blockade in adult wild-type mice increases fatigability.
Muscles of Mstn -/mice, a model of constitutive inhibition of signaling via ActRIIB, exhibit a congenital fiber-type profile that is characterized by an increase in the number of fast "glycolytic" (MHCIIB) fibers and concomitant loss of "oxidative" (MHCI, MHCIIA) fibers, which entails changes in muscle function, exercise capacity and muscle metabolism 4, 7, 8, 18, 19 . To circumvent the effects of congenital fiber-type switching, we here inhibited ActRIIB signaling in adult wild-type mice with a soluble form of the activin receptor fused with the Fc-fragment of mouse IgG (sAc-tRIIB-Fc). Four months of treatment promoted robust skeletal muscle growth together with a significant increase in total body weight, confirming previously published data (Fig. S1) 20 .
Importantly, the increase in muscle mass was not accompanied by fiber-type conversion (Fig.   S2 ). The absolute maximal force of EDL and soleus muscle increased in parallel with muscle size (Figs. 1a,c). Specific maximal force was conserved, implicating a proportional increase of force and muscle mass ( Fig. 1b) . However, sActRIIB-Fc treatment also increased muscle fatigue ( Figs. 1c,d ) and mice exhausted precociously during incremental speed running tests ( Figs. 1e,g) . Serum lactate, being already significantly increased at resting state, rose to pathological levels following incremental speed running ( Figs. 1f,g) . The concept of "Critical Speed" accurately reflects the capacity for aerobic exercise and is based on the proportional relationship between "covered distance" and "time to exhaustion" at different velocities 21 .
During the four months treatment period, we found a steady decline in Critical Speed in the treatment and control group, however, the decline over time was by far larger in sActRIIB-Fc treated animals as compared to PBS-treated mice (Figs. 1h,i).
Severe exercise intolerance in dystrophic mdx mice following treatment with sActRIIB-Fc.
In Duchenne muscular dystrophy and its mdx mouse model, oxidative metabolism is compromised due to membrane damage and the resulting intracellular calcium overload [15] [16] [17] . Having shown that ActRIIB blockade decreased aerobic exercise capacity in wild-type mice, we now investigated what effect administration of sActRIIB-Fc would have on the metabolic phenotype of mdx mice. This information would have important clinical implications for the strategies to use ActRIIB blockade for treatment of muscular dystrophies. Despite a massive increase in skeletal muscle mass after sActRIIB-Fc treatment ( Fig. S1) , absolute maximal force decreased in soleus muscle and most notably specific force in both EDL and soleus muscles ( Figs. 2a,b) , serving as functional evidence for increased myopathic changes of sAc-tRIIB-treated dystrophic mdx muscle. Interestingly, sActRIIB-Fc treatment did not cause any greater force decline during repetitive stimulation ( Figs. 2c,d) . Electromyography excluded problems in neuromuscular transmission but revealed abnormal spontaneous potentials and the presence of complex repetitive discharges in both PBS and sActRIIB-Fc treatment groups of the mdx mice ( Fig. S3 ). Such polyphasic potentials are characteristic of dystrophic mdx muscle 22 . As voluntary motor activity seemed reduced when observing sActRIIB-Fc treated mdx mice, we proceeded to analyze their exercise behavior. Remarkably, at the end of the treatment period, sActRIIB-Fc treated mdx mice suffered from severe exercise intolerance associated with a pathological serum lactate increase (Figs. 2e-g, Supplemental Video). It is important to note, that exercise capacity of mdx mice declined throughout the four months treatment period, however, to a far larger extent in sActRIIB-Fc treated mdx mice than in the PBS-treated control group (Figs. 2h,i) .
sActRIIB-Fc treatment affects muscle capillarization.
The ability of mitochondria to produce ATP critically depends on the oxygen supply via tissue blood perfusion, thus a combination of hypoperfusion plus exercise induced hypoxemia might explain the severe exercise intolerance. Treatment with sActRIIB-Fc caused a drop in capillary density especially in the oxidative soleus muscle from mdx mice with a subsequent increase in the capillary domain ( Figs. 3a-d) . The increase of the capillary domain was also found in glycolytic EDL muscles of mdx mice, albeit to a lesser degree ( Fig. S4a-d ). Treatment of mice as well as of C 2 C 12 myotubes with sActRIIB-Fc down-regulated expression of Vegf-A suggesting an indirect negative effect of myostatin blockade on capillary formation (Figs. 3e,f). Interestingly, Vegf-A expression in mdx mice was much lower than in wild-type mice, and treatment with sAc-tRIIB-Fc did not decrease Vegf-A mRNA-abundance any further ( Fig. 3e ), suggesting the presence of additional mechanisms for regulating capillary density. In this regard the findings of Hayot et al. (2010) are of special interest, who reported an induction of myostatin expression in muscles of rats exposed to chronic hypoxia and in patients with chronic obstructive pulmonary disease (COPD). The authors interpreted these findings as a potential cause for the muscle wasting that is often seen in COPD-patients 23 . These findings, however, could also be interpreted as a compensatory up-regulation of myostatin to improve the metabolic functioning and to increase capillary density in a state of chronic hypoxia. It is of special interest that endothelial cells strongly express the mRNAs of transmembrane receptors (ActRIIA/B and ALK4/5) for myostatin or its homologs, whereas myostatin mRNA was only expressed at low levels ( Fig. 3g) . Treatment of endothelial cells (HUVEC cell line) with increasing dosages of recombinant myostatin in vitro increased the cell doubling time in culture, verifying a direct effect of myostatin or its homologs on endothelial cell proliferation ( Fig. S4e) , however, the exact ligands of muscle endothelial cell regulation in vivo remain to be determined.
ActRIIB signaling regulates Pgc1α and Ppar transcription factors. The exercise intolerance
and lactic acidosis following ActRIIB blockade suggests underlying changes in muscle metabolism, a hypothesis supported by previous transcriptome profiling 13 . In agreement, we show that the copy numbers of Pgc1α and Pparβ, which are key transcription factors promoting oxidative metabolism in skeletal muscle, are down-regulated after treatment with sActRIIB-Fc (Figs. 4b,c ) and following treatment of C 2 C 12 myotubes with sActRIIB-Fc ( Fig. 4g) . On the protein level, down-regulation of Pgc1α was more pronounced in the mdx muscle if referred to desmin abundance ( Fig. 4a) . Such loss of oxidative properties was accompanied by a compensatory activity increase of enolase, a key glycolytic enzyme ( Fig. 4d ). Furthermore, mRNA levels of Pdk4, an inhibitor of pyruvate dehydrogenase (Pdh) and a regulatory switch of substrate utilization from glucose towards fatty acids 24 , was strongly decreased following sActRIIB-Fc treatment in mdx mice ( Fig. 4e) . We thus expected an inhibitory effect of sAc-vRIIB-Fc treatment on β-oxidation and found a down-regulation of Cpt1b mRNA levels ( Fig.   4f ). Likewise, sActRIIB-Fc treatment of C 2 C 12 myotubes reduced expression of genes controlling oxidative metabolism and β-oxidation within 24 hours of treatment ( Fig. 4g) , implying a direct effect of myostatin signaling in the regulation of these genes.
We further focused our attention on the neuronal nitric oxide synthase (Nos1, nNos), because it is well known that the sarcolemmal presence of the Nos1 enzyme is strongly reduced in the absence of its binding partner dystrophin in patients with DMD and in mdx mice 25, 26 . The resulting dysregulation of NO-synthesis entails a failure of contraction induced vasodilatation as well as changes in the cellular calcium homeostasis associated with exacerbated post-exercise fatigability, exercise-induced muscle edema and cell necrosis 27, 28 . We thus wondered, whether sActRIIB-Fc treatment would influence sarcolemmal Nos1 expression, hence further compromising the pathophysiological effect of sActRIIB-Fc on vasculature and oxidative metabolism. As expected, we found a strong decrease of Nos1 mRNA copy numbers in mdx muscles of both treatment groups in comparison to wild-type muscle ( Fig. S11a) , which was paralleled by a strong decrease of sarcolemmal expression of Nos1 protein in mdx muscle ( Fig.   S11b ). Furthermore, treatment with sActRIIB-Fc diminished Nos1 transcription in wild-type and mdx muscle ( Fig. S11a) . However, subsarcolemmal Nos1 protein content remained unchanged ( Fig. S11b) , and Western blot did not reveal any changes in Nos1 protein levels in wild-type mice (Fig. S11c) , whereas Nos1 protein levels in mdx mice were below detection levels (data not shown). This suggests that sActRIIB-Fc treatment unlikely aggravates NO dysregulation of dystrophin deficient muscle, although further experiments are required to ascertain or to exclude a role of the ActRIIB-receptor on NO signaling.
Reduced oxidative metabolism in mdx muscle following treatment with sActRIIB-Fc. It
should be noted that the mRNA and protein levels of key regulatory genes (Pparβ, Pgc1α) important for oxidative metabolism (Figs. 4a-c) were significantly lower in mdx than in wildtype mice, supporting previous findings that oxidative muscle metabolism is depressed in dystrophic muscle to some extent 15, 29 .
We therefore studied in real-time the response of the oxidative metabolism to a standardized bout of exercise in anesthetized mdx mice either treated with PBS (controls) or sActRIIB-Fc.
Muscle function and energy metabolism were assessed strictly noninvasively in calf muscle with an innovative experimental setup using phosphorus ( 31 P) nuclear magnetic resonance spectroscopy (MRS) 30 . An exercise bout of six minutes consisting of repeated maximal isometric contractions was induced in vivo by transcutaneous electro-stimulation. After induced repeated contractions fatigue levels ( Fig. 5a) , intracellular acidosis ( Fig. 5b) reflecting a compensatory increase in response to decreased aerobic energy production. Furthermore, mitochondrial DNA (mtDNA) copy numbers remained largely unchanged following treatment with sActRIIB-Fc (Fig. S8a) . The normal mtDNA copy numbers together with unaltered CS enzyme activities ( Fig. S5a,b ) let us conclude that ActRIIB blockade did not affect mitochondrial mass.
Treatment with sActRIIB-Fc down-regulates porin expression in wild-type and mdx mus-
cle. Given the abnormal post-exercise PCr re-synthesis (τPCr) along with normal respiratory chain activities, we wondered whether the ATP transport from the mitochondrial matrix into the cytosol of skeletal muscle cells might be affected, which might explain the diminished rate of aerobic energy production. Keeping with such hypothesis, decreased protein levels of Vdac3 had already been reported for mdx muscle, hinting towards a derangement of the ADP/ATP-shuttling system through the outer mitochondrial membrane via the Voltage Dependent Anion Channels (Vdac, syn. porin) 31, 32, 33 . In line with these findings, a proteomic survey of differentially expressed proteins from wild-type and mdx mouse hearts had discovered a substantial loss of Vdac1 protein 34 . Indeed, here we show that wild-type and to an even larger extent mdx muscles exhibited a considerable reduction of Porin mRNA-transcripts Muscle degeneration is accompanied by a leak of cytoplasmic enzymes such as creatine kinase (CK). We measured serum CK levels, which were largely elevated in mdx mice from both treatment groups; however, we did not detect any significant differences since interindividual variation was large ( Fig. S10b) . In mdx mice, muscle degeneration is followed by excessive regeneration with abundant splitting of regenerated fibers, which appear as small fiber profiles on transverse sections. Such excessive regeneration leads to an increase of muscle mass (see comparison between wild-type and mdx mice: Fig. S1 ). Following treatment with sActRIIB-Fc, muscles enlarged on average, if compared to PBS treatment, by ≈1.6 fold in mdx and by ≈1.3 fold in wild-type mice (Fig. S1) . However, analysis of morphometric features of EDL muscles from sActRIIB-Fc treated mdx mice, revealed a further increase in the number of small fiber profiles if compared to PBS-treated mdx mice (Fig. S10c) . This finding suggestes that the excessive increase of muscle weight was triggered by abnormal regeneration and not by fiber hypertrophy. The soleus muscle of mdx mice, while not increasing its mass after sActRIIB-Fc treatment, exhibited an increased fiber size variation (Fig. S10d) . In conclusion, the dystrophic phenotype of dystrophin deficient muscle persisted or even increased following treatment with sActRIIB-Fc.
DISCUSSION
Myostatin/ActRIIB signaling exerts three major functions on skeletal muscle. (i) It acts to limit its size, (ii) promotes oxidative properties, and (iii) balances glucose versus fat utilization. The changes in muscle physiology in hypermuscular mice following treatment of adult mice with sActRIIB-Fc highlights the fact that myostatin/ActRIIB blockade confers little functional advantage over wild-type muscle due to its rapid fatigability. Improved muscle strength, however short lived, comes at the cost of increased fatigability and exercise intolerance, which is often seen in patients with mitochondrial disorders such as MELAS or MERRF syndrome 35 . Interestingly, muscle cramps are frequently observed in whippet dogs with homozygous Mstn mutations 36 . Moreover, "double muscle cattle", several breeds of which have been identified to carry Mstn mutations 37, 38 , are prone to exercise induced lactic acidosis and severe rhabdomyolysis 39, 40 . In myostatin deficient animals, such exercise failure could be attributed to congenital fiber-type disproportion with a shift towards the expression of the fast IIB myosin heavy chain (MHC) isoform 4, 18 , which is well known to be associated with loss of oxidative properties of skeletal muscle and increased fatigability 5, 8 . In contrast to animals born with mutations in the Mstn gene, we show that blockade of ActRIIB signaling in adult wild-type mice beyond the period of muscle development does not have any impact on fibertype composition, thus confirming previous reports 10 .
After sActRIIB-Fc treatment, the mice exhibit clinical signs of early muscle fatigue, exercise intolerance, and lactic acidosis -characteristic signs for a depression of β-oxidation, a shift towards anaerobic glycolysis, and ATP-deficiency. Interestingly, whereas ex vivo mitochondrial respiratory chain enzyme activities and mtDNA copy numbers were within the normal range, in vivo 31 P-MRS clearly demonstrated a down-regulation of oxidative energy metabolism in sActRIIB-Fc treated mdx mice. We further demonstrate a significant loss of the Porin complex in sActRIIB-Fc treated mice, pointing towards an underlying defect of ATPhandling and ATP-transport as one causative mechanism for the metabolic phenotype. A second aggravating factor, which further compromised exercise tolerance, is the decrease of capillary density and the increase of the capillary domain. Previous reports attributed such reduced capillary density to the increase of muscle fiber size 41 . However, here we demonstrate a net numerical loss of capillaries per fiber following treatment with sActRIIB-Fc. This finding was most pronounced in mdx mice with a profound rarefication of the capillary bed in dystrophic muscle. In dystrophinopathies diminished sarcolemmal Nos1 results in dysregulation of the capillary adaptive response to exercise leading to functional muscle ischemia 42 .
Our protein analysis argues against a further aggravation of the capillary adaptive response by additional loss of Nos1 in sActRIIB-Fc treated animals, despite the fact that Nos1 mRNA levels were clearly reduced. sActRIIB-Fc treatment of dystrophic mdx mice dramatically worsened the myopathic phenotype as shown by the large deficit in specific force. As lack of dystrophin per se alters mitochondrial function in DMD patients and mdx mice 15, 16, 29 , the blockade of myostatin signaling initiates a vicious cycle resulting in severe secondary metabolic myopathy. We also found an increased fiber size variation after sActRIIB-Fc treatment of mdx mice pointing towards increased myopathic changes even at the tissue level.
In the past, several investigators have used different strategies of interfering with the ActRIIB receptor mediated signaling pathway in order to treat mdx mice and GRMD dogs. This was done either through injection of sActRIIB-Fc 12,43 , AAV-mediated gene transfer 11 or antibodies directed against the ActRIIB receptor 44 . Overall, the conclusions were optimistic about the usefulness of such strategy to treat dystrophinopathies. However, it should be noted that our results and conclusions differ from previously published work in various aspects. We think the reason for that mainly lies in the choice of endpoints to define success or failure of such a treatment. For DMD patients, clinically relevant and quantifiable improvements would comprise better performance in the six-minutes walk 45 and improvement of respiratory function.
This implies the ability of the patient's body to maintain a certain workload for a prolonged time period and not just to be able to produce single bouts of maximum short-duration muscle activity as tested by tetanic muscle contractions 11, 12 or by the whole body tension method 43 . In most studies, the increase of muscle size was taken as an endpoint 11, 44 , automatically assuming that big muscles are healthier muscles. This basic assumption is put into question by our results. None of the studies investigated endurance capacity, which evaluates the effect of a treatment on the physiology of the entire body over a longer time period and would thus be a relevant parameter that could translate into improvement of life quality in patients. Several studies, one using the identical sActRIIB-Fc compound 12 , reported a small, but significant decline of CK values after ActRIIB blockade 11, 12 . We were unable to reproduce this finding, the reason for these differences remaining unresolved.
We show that myostatin controls the metabolic profile of skeletal muscle, and its blockade depresses the main molecular determinants of oxidative metabolism and β-oxidation. Interestingly, genetic inactivation of Pparβ, similar to myostatin/ActRIIB blockade, reduced oxidative properties of skeletal muscle 46 . This adds further evidence that myostatin controls the muscle oxidative phenotype via peroxisome proliferator-activated receptors (PPAR) and Pgc1α, the downstream target of Pparβ, while the down-regulation of Pdk4 indicates a shift away from β-oxidation towards glucose metabolism. These qPCR data are strongly corroborated by a recent transcriptome study following treatment with sActRIIB-Fc of wild-type mice 13 . However, we lack direct evidence to ascertain a shift towards higher glucose metabolism, although the down-regulation of Pdk4 and up-regulation of Enolase can be counted as indirect indicators for such a change. The unfavorable combination of decreased vascularization and metabolic changes after ActRIIB blockade is likely to cause a rapid imbalance between increased cytosolic ATP hydrolysis and insufficient mitochondrial ATP synthesis during exhaustive exercise. The subsequent shift towards anaerobic glycolytic ATP synthesis explains the rapid fatigability and the pathologically increased lactate production 47 . However, the metabolic adaption in response to myostatin may differ in diverse physiological and pathophysiological contexts, e.g. myostatin inhibition was reported to improve motor performance in aged mice 48 . Further work is required to elucidate the metabolic function of myostatin in different disease situations and during ageing.
In conclusion, our results suggest that myostatin/ActRIIB signaling optimizes oxidative meta- 
MATERIALS AND METHODS
Animals.
Male mdx mice (on a C57BL/10ScSn background) were bred in the animal facility of the Medical Faculty of Paris VI and kept according to institutional guidelines. Wild-type male C57BL/6J control mice were purchased from Charles River (France). Two-months-old wild-type and mdx mice were injected twice weekly subcutaneously with 10 mg/kg with the rodent form of the soluble activin receptor IIB (sActRIIB-Fc; Acceleron Pharma) for a total of four months before sacrifice. The methods of sActRIIB-Fc synthesis have previously been described 49 . All animal studies have been approved and were carried out under the laboratory and animal facility licenses A75-13-11 and A91-228-107.
Evaluation of the critical speed.
Mice were subjected to three or four separate bouts of runs until exhaustion at various treadmill speeds (between 20 and 80 cm/s according to individual motor capacity, one run per day) according to previously published protocols 21 
Morphometric analysis of capillary number and capillary domains: Cryosections of 12
µm of the EDL and soleus muscles of PBS-and sActRIIB-Fc treated animals were stained with anti-laminin to delineate the muscle fibers. Muscle capillaries were stained with anti-CD31. Fluorescent photographs were taken with a 20x objective on a Microscope (Zeiss, AxioImager Z1) and saved as TIFF files. These images were projected on a flatscreen coupled with a graphic tablet, which enabled the manual retracing of the muscle fiber outlines and the counting of capillaries that were found around it. For the EDL, the fibers of the entire muscle cross section were analyzed, and for the soleus muscle, the fibers from 10 representative nonoverlapping visual fields. For each muscle fiber we determined the cross sectional plane 
In vivo MRS investigation of muscle function and oxidative metabolism.
Mice were anesthetized with 4% isoflurane in 100% air at a flow of 3 l/min and were placed into a home-built cradle specifically designed for the strictly noninvasive MRS investigation of muscle function and energetics 30 . Throughout the experiment, anesthesia was maintained using a facemask continuously supplying 1.75% isoflurane in 33% O 2 (0.2 l/min) and 66% N 2 O (0.4 l/min). 
